This NOFO invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs).

This NOFO seeks to promote critical target validation approaches to help de-risk subsequent translational

credit: Wikimedia Commons

How's Your Community Doing?
Check Out it's
Community Vital Signs

research and accelerate the advancement of novel therapies for ADRD.

Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples.

In its initial phase, this FOA provided support for up to two years (R61 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models.

Upon demonstration of technical feasibilities, a second phase (R33 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines.

Applicants responding to this NOFO must address objectives for both the R61 and R33 phases and are expected to have a substantial collaborative effort between independents laboratories.

This NOFO is not specific for any one or group within the ADRD spectrum of disorders.

Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED).